ACADIA Pharmaceuticals Appoints Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs & Chief...
November 04 2019 - 9:00AM
Business Wire
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the
appointment of Ponni Subbiah, M.D., M.P.H., as Senior Vice
President, Global Head of Medical Affairs and Chief Medical
Officer. Dr. Subbiah will report to Serge Stankovic, M.D.,
M.S.P.H., ACADIA’s President and be responsible for corporate
medical affairs including medical strategy, scientific
communications, and medical science liaison activities.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20191104005143/en/
Ponni Subbiah, M.D., M.P.H., Senior Vice
President, Global Head of Medical Affairs and Chief Medical Officer
(Photo: Business Wire)
“I am very excited to welcome Ponni to our executive team. Her
extensive experience as a clinician and pharmaceutical physician as
well as her strong leadership track record in global medical and
scientific affairs, are extremely valuable at this transformational
time for our organization,” said Dr. Serge Stankovic.
“ACADIA has transformed treatment of patients with Parkinson’s
disease psychosis and has the potential to also play a crucial role
in how we continue to improve the lives of patients with other CNS
disorders," said Dr. Subbiah. “I am excited to join ACADIA on this
journey and use my relevant medical affairs and clinical
development experience to advance the company’s strong portfolio of
approved and investigational programs for some of today’s biggest
challenges in neuro health.”
Dr. Subbiah is a neurologist with over 20 years of experience in
the pharmaceutical industry and global health sector. She has led
the development and execution of medical and clinical research
strategies in various therapeutic areas, including neurology,
psychiatry, opioid addiction, pain, oncology, diabetes, urology,
inflammation, respiratory, and infectious diseases.
Dr. Subbiah was most recently Chief Medical Officer for Indivior
Inc., with responsibility for pharmacovigilance and medical affairs
globally. She was also the company spokesperson at policy
discussions including testifying at the Presidential Commission on
Combating Drug Addiction and Opioid Crisis and the hearing by the
House Committee on Energy & Commerce on the opioid crisis.
During her previous tenure of over 15 years at Pfizer, Inc., she
held various leadership roles in global medical affairs and led
Pfizer’s Global Access program to improve healthcare access for
low-income populations in the developing world through approaches
that were commercially viable and sustainable.
Dr. Subbiah received her medical degree from Madras Medical
College in Chennai, India and completed a residency in neurology at
the Mayo Graduate School of Medicine in Rochester, MN. She
completed a research/clinical fellowship in AIDS Neurology at Johns
Hopkins University School of Medicine and earned a Master’s degree
in Public Health from the Johns Hopkins Bloomberg School of Public
Health in Baltimore, MD.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development
and commercialization of innovative medicines to address unmet
medical needs in central nervous system disorders. ACADIA has
developed and commercialized the first and only medicine approved
for the treatment of hallucinations and delusions associated with
Parkinson’s disease psychosis. ACADIA also has ongoing clinical
development efforts in additional areas with significant unmet
need, including dementia-related psychosis, schizophrenia, major
depressive disorder, and Rett syndrome. This press release and
further information about ACADIA can be found at:
www.acadia-pharm.com.
Forward-Looking Statements
Statements in this press release that are not strictly
historical in nature are forward-looking statements. These
statements include but are not limited to statements regarding the
timing of future events. These statements are only predictions
based on current information and expectations and involve a number
of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to
various factors, including the risks and uncertainties inherent in
drug development, approval and commercialization. For a discussion
of these and other factors, please refer to ACADIA’s annual report
on Form 10-K for the year ended December 31, 2018 as well as
ACADIA’s subsequent filings with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
This caution is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and ACADIA undertakes no obligation to revise
or update this press release to reflect events or circumstances
after the date hereof, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191104005143/en/
Investor Contact: ACADIA Pharmaceuticals Inc. Mark Johnson, CFA
(858) 261-2771 ir@acadia-pharm.com
Media Contact: ACADIA Pharmaceuticals Inc. Maurissa Messier
(858) 768-6068 media@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Sep 2023 to Sep 2024